Non-pegylated liposomal doxorubicin plus ifosfamide in metastatic soft tissue sarcoma: results from a phase-II trial.
Rita De Sanctis(Humanitas University), Armando Santoro(IRCCS Humanitas Research Hospital), Alessandro Comandone(Ospedale Humanitas Gradenigo), Alexia Bertuzzi(Humanitas University), Piergiuseppe Colombo(Humanitas University), Silvia Marchetti(Institute of Cancer Research), Romano Fabio Lutman(Humanitas University), Laura Giordano(Istituti di Ricovero e Cura a Carattere Scientifico), Umberto Basso(Istituto Oncologico Veneto), Andrea Marrari(IRCCS Humanitas Research Hospital)
PubMed
January 1, 2015
Cited by 18
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
|JAMA|2014|569
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532